Dr Reddy's Strengthens Russian OTC Portfolio Through Glenmark Deal
Executive Summary
Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from India's Glenmark.
You may also be interested in...
Glenmark Builds US OTC Lineup In Wockhardt Deal
Glenmark acquires a portfolio of generic OTCs from Wockhardt marketed in US including famotidine 10- and 20-mgs; cetirizine 5- and 10-mgs; lansoprazole 15-mg delayed-release; and olopatadine hydrochloride 0.1% ophthalmic solution.
Dr Reddy’s Enters OTC Eyecare Space
Dr Reddy’s has announced the launch of its OTC versions of Pataday olopatadine solution in the US. The firm’s entry into the OTC eyecare space follows other OTC launches of rivals to Voltaren and Nicorette earlier this year.
Stada Grows Twice As Fast As CHC Market In 2023
Stada's local brand focus helped it deliver Consumer Healthcare sales growth of 16% in 2023 ensuring the German firm significantly outpaced the overall market growth rate of 7%.